Company profile
ORIC PHARMACEUTICALS, INC.
NASDAQ:ORICBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ORIC-101 | phase1 | — | 4 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07723248 | phase3 | recruiting | 2026-08-03 | 2028-03-01 | ORIC Pharmaceuticals | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) |
| NCT06012721 | phase1 | completed | 2023-09-11 | 2023-11-23 | ORIC Pharmaceuticals | Effect of Food on the Pharmacokinetics of ORIC-114 |
| NCT06816992 | phase1 | recruiting | 2025-02-27 | 2026-12-01 | ORIC Pharmaceuticals | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC |
| NCT03835637 | phase1 | completed | 2018-03-23 | 2018-07-04 | ORIC Pharmaceuticals | Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects |
| NCT03928314 | phase1 | terminated | 2019-05-02 | 2022-09-22 | ORIC Pharmaceuticals | Study of ORIC-101 in Combination With Anticancer Therapy |
FDA applications (0)
No records yet.